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Figure 1 Effect of Niacin on HDL-C Levels and Metrics of Functionality
Mean percent change from baseline for each treatment group is depicted for high-
density lipoprotein cholesterol (HDL-C) levels, cholesterol efﬂux capacity, and HDL
inﬂammatory index. *Indicates p value of < 0.05 for change compared with
placebo. CI ¼ conﬁdence interval; ER ¼ extended release.
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1910coefﬁcient of variation was 5.5% for cholesterol efﬂux capacity and
4.3% for HDL inﬂammatory index.
Bivariate correlation analysis demonstrated a moderate associa-
tion (r ¼ 0.56; p ¼ 0.002) between HDL-C levels and cholesterol
efﬂux capacity. However, no signiﬁcant association was noted
between HDL inﬂammatory index and either HDL-C levels
(r ¼ 0.18) or cholesterol efﬂux capacity (r ¼ 0.16). Only the
HDL inﬂammatory index was associated with log-transformed
values of C-reactive protein (r ¼ 0.37; p ¼ 0.02).
The impact of the 2 treatment regimens on HDL-C levels and
functional metrics are displayed in Figure 1. As expected, the
addition of niacin therapy led to a robust increase in average HDL-
C from 46 to 57 mg/dl (p ¼ 0.001 compared with baseline;
p ¼ 0.001 compared with placebo). However, no change was noted
in either cholesterol efﬂux capacity (mean change 1%; 95%
conﬁdence interval: 11% to 10%) or HDL inﬂammatory index
(mean change 9%; 95% conﬁdence interval: 6% to 24%).
These results thus indicate the feasibility of using 2 comple-
mentary assays of HDL function in a small drug study. The
addition of niacin to statin therapy led to favorable changes in
patients’ lipid proﬁles without a demonstrable effect on HDL
functionality, thus providing one potential mechanistic hypothesis
for the disappointing results in recent clinical trials.
The strengths of this study include its randomized, placebo-
controlled, prospective design and the use of robust assays with
previous relationship to cardiovascular disease phenotypes. Limita-
tions include small size, although the matched-pairs statistical plan
afforded 80% power to detect a 13% and 15% improvement
in cholesterol efﬂux capacity and HDL inﬂammatory index,
respectively. Furthermore, any potentially beneﬁcial effect of niacin
via LDL-C or lipoprotein(a) reduction would not have been detected
owing to the HDL speciﬁcity of the assays. (Carotid Atherosclerosis
Regression at Magnetic Resonance Assessment; NCT00307307).*Amit V. Khera, MDy
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687.e1–8.Letters to the Editor
Pregnancy in Arrhythmogenic
Right Ventricular Dysplasia/
CardiomyopathyWe read with interest the paper by Marcus et al. (1) published
in the May 14, 2013 issue of the Journal. The authors brought
to light the complex nature of clinical genetics in arrhythmogenic
right ventricular cardiomyopathy (ARVC) patients. Overall, this
paper provides an important review of the current state of clinical
genetic testing for this rare condition. We applaud the authors
for their conﬁrmation of the Heart Rhythm Society/European
Heart Rhythm Association guidelines (2) in recommending
genetic counseling when ordering genetic testing in this and other
cardiomyopathies.
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1911The Johns Hopkins arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C) program was established in 1999 with
3 goals: 1) to educate patients and physicians about ARVD/C; 2) to
evaluate and manage patients with known or suspected ARVD/C;
and 3) to contribute to the body of literature regarding this
condition. The program has facilitated the clinical evaluation of
over 1,140 patients and follows over 250 families with conﬁrmed
disease enrolled in the registry. In-house clinical protocols have
been established for managing these families.
The management of ARVD/C patients during pregnancy was 1
of the important clinical issues raised by the authors. Pregnancy
among ARVD/C patients in the literature is scarce except for
scattered case reports and the important series published by Bauce
et al. (3) in 2006. With the proliferation of genetic testing and
increased recognition of ARVD/C, earlier diagnoses have become
possible. During the 14 years our program has been in existence,
we have cared for a considerable number of arrhythmogenic right
ventricular dysplasia (ARVD) patients who became pregnant.
Each of these patients did well during and following pregnancy. In
our center, we advise Holter monitoring at 7 months gestation,
integration of the cardiac and obstetrical team in planning for
delivery, and echocardiogram and Holter monitoring 3 months
postpartum. We agree that for the ARVD/C patient considering
pregnancy, it is important to discuss the psychosocial issues
surrounding passing on a genetic disease. Fortunately, the pene-
trance of ARVD is low, the expressivity of disease is variable, and,
most importantly, ARVD is associated in most patients with
a high quality of life and a near-normal life expectancy.
We would caution the reader regarding the authors’ suggestion
of in vitro fertilization to conceive embryos without a mutation, if
known in the family. This is an expensive and invasive option that
is, in our experience, unnecessary. As the authors themselves note,
digenic inheritance is not uncommon in ARVD/C (4); therefore,
pre-implantation genetic diagnosis may not guarantee that the
child will not be at risk of developing disease, limiting possible
effectiveness. We advise considerable counseling and caution in
utilizing this procedure in the setting of solely hoping to avoid
ARVD/C in the offspring. Also, regarding amniocentesis to eval-
uate for ARVD/C-associated mutations, the risk and beneﬁts
of this invasive procedure, including a well-appreciated risk of
miscarriage, should be thoroughly discussed.
Marcus et al. (1) provide a tool to update physicians regarding
genetic testing options to be utilized in the setting of genetic
counseling. We hope, however, that an accurate message is por-
trayed regarding pregnancy in ARVD/C patients and the use of
genetic testing technology in such a setting.
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428–35.ReplyPregnancy in Arrhythmogenic Right
Ventricular Dysplasia/CardiomyopathyWe thank the members of the Johns Hopkins arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C) program for their
comments regarding our paper (1). The objective of our paper was
to provide complete information to physicians and their patients
about the genetics of ARVD/C, including all aspects of the
inheritance of ARVD/C. In vitro fertilization was included because
this is an option for parents to have a child without the possibility
of the child developing this condition if 1 of the parents has
a pathological gene for arrhythmogenic right ventricular cardio-
myopathy. We are not advocating this; we are simply indicating
that this option exists. As noted in our report (1), this disease is
autosomal dominant, and the offspring has a 50% chance of
inheriting the disease if 1 of the parents has an abnormal gene.
Although the penetrance is variable, the possibility of the disease
expression in the offspring of the parent with a known gene defect
is deﬁnitely present and parents need to be aware of this. If the
offspring develops arrhythmogenic right ventricular cardiomyop-
athy, the parents may feel guilty about having knowingly taken the
risk of transmitting the disease.*Frank I. Marcus, MD
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